Cargando…

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

IMPORTANCE: Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes. OBJECTIVE: To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: TRAILBLAZER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pontecorvo, Michael J., Lu, Ming, Burnham, Samantha C., Schade, Andrew E., Dage, Jeffrey L., Shcherbinin, Sergey, Collins, Emily C., Sims, John R., Mintun, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577883/ https://www.ncbi.nlm.nih.gov/pubmed/36251300 http://dx.doi.org/10.1001/jamaneurol.2022.3392

Ejemplares similares

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
por: Wessels, Alette M., et al.
Publicado: (2023)

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease
por: Gueorguieva, Ivelina, et al.
Publicado: (2023)

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
por: Lowe, Stephen Loucian, et al.
Publicado: (2021)

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
por: Wessels, Alette M., et al.
Publicado: (2020)

Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
por: Rashad, Areeba, et al.
Publicado: (2022)

AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease
por: Mizuno, Satoshi, et al.
Publicado: (2012)

Signature of Alzheimer’s Disease in Intestinal Microbiome: Results From the AlzBiom Study
por: Laske, Christoph, et al.
Publicado: (2022)

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
por: Shcherbinin, Sergey, et al.
Publicado: (2023)

TRAILblazing Strategies for Cancer Treatment
por: Kretz, Anna-Laura, et al.
Publicado: (2019)

Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective
por: Volloch, Vladimir, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial
por: Willis, Brian A., et al.
Publicado: (2023)

Neural crest migration: trailblazing ahead
por: Kulesa, Paul M., et al.
Publicado: (2015)

Online psychotherapy: trailblazing digital healthcare
por: McDonald, Annabel, et al.
Publicado: (2020)

Paul Berg: Recombinant DNA trailblazer
por: Goff, Stephen P., et al.
Publicado: (2023)

AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research
por: Liu, Haibin, et al.
Publicado: (2014)

AlzPharm: integration of neurodegeneration data using RDF
por: Lam, Hugo YK, et al.
Publicado: (2007)

Trailblazer: the power of business as the greatest platform for change
por: Benioff, Marc
Publicado: (2019)

Trailblazing Precision Oncology for Rare Tumor Subtypes
por: Shee, Kevin, et al.
Publicado: (2017)

Kelvin Kong: trailblazer for Indigenous health in Australia
por: Lane, Richard
Publicado: (2020)

Trailblazing through the Opioid Epidemic. Will Science Prevail?
por: Limratana, Panop, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
por: Hey, John A., et al.
Publicado: (2017)

Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome
por: Bouter, Yvonne, et al.
Publicado: (2022)

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
por: Zhou, Yadi, et al.
Publicado: (2021)

Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
por: Sandberg, Anders, et al.
Publicado: (2022)

Trailblazing Medicine: Sustaining Explorers During Interplanetary Missions
por: Seedhouse, Erik
Publicado: (2011)

TV outside the box: trailblazing in the digital television revolution
por: Landau, Neil
Publicado: (2016)

Chung Un Lee: the trailblazer of tropical medicine in China
por: Liu, Huan, et al.
Publicado: (2022)

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
por: Zimmer, Jennifer A., et al.
Publicado: (2021)

ILC2s—Trailblazers in the Host Response Against Intestinal Helminths
por: Bouchery, Tiffany, et al.
Publicado: (2019)

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease
por: Pontecorvo, Michael J, et al.
Publicado: (2011)

CAD-ALZ: A Blockwise Fine-Tuning Strategy on Convolutional Model and Random Forest Classifier for Recognition of Multistage Alzheimer’s Disease
por: Abbas, Qaisar, et al.
Publicado: (2023)

The Courage to Take Command: Leadership Lessons from a Military Trailblazer
por: Morgenthaler, Jill
Publicado: (2014)

Learning from a Trailblazer in Dermatology: An Interview with Jean Bolognia, MD
por: Olamiju, Brianna
Publicado: (2020)

Are trailblazing trials for reducing cognitive decline putting the cart before the horse?
por: Daly, Timothy
Publicado: (2022)

Marilyn T. Miller: A trailblazer with a vision for sight sans frontiers
por: Bansal, Rolika, et al.
Publicado: (2022)

James W. Valentine (1926–2023): Trailblazing paleobiologist with an enduring legacy
por: Jablonski, David
Publicado: (2023)

Plasma protein biomarkers trailblaze as early predictors of type 1 diabetes
por: Jia, Xiaojing, et al.
Publicado: (2023)

Meta Analysis of Human AlzGene Database: Benefits and Limitations of Using C. elegans for the Study of Alzheimer's Disease and Co-morbid Conditions
por: Vahdati Nia, Behrad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m0d4l0mr4v7adhkicktbotgprh